{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=2&sponsor=Biomedical+Advanced+Research+and+Development+Authority",
    "query": {
      "sponsor": "Biomedical Advanced Research and Development Authority",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 110,
    "total_pages": 11,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=3&sponsor=Biomedical+Advanced+Research+and+Development+Authority&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=1&sponsor=Biomedical+Advanced+Research+and+Development+Authority&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-04T08:15:19.986Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04470427",
      "title": "A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "SARS-CoV-2"
      ],
      "interventions": [
        {
          "name": "mRNA-1273",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "ModernaTX, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30415,
      "start_date": "2020-07-27",
      "completion_date": "2022-12-29",
      "has_results": true,
      "last_update_posted_date": "2024-03-21",
      "last_synced_at": "2026-10-04T08:15:19.986Z",
      "location_count": 100,
      "location_summary": "Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 79 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04470427"
    },
    {
      "nct_id": "NCT03014089",
      "title": "Safety, Tolerability, and Immunogenicity of mRNA-1325 in Healthy Adult Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Zika Virus"
      ],
      "interventions": [
        {
          "name": "mRNA-1325",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "ModernaTX, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 90,
      "start_date": "2016-12-21",
      "completion_date": "2019-07-31",
      "has_results": true,
      "last_update_posted_date": "2024-08-21",
      "last_synced_at": "2026-10-04T08:15:19.986Z",
      "location_count": 3,
      "location_summary": "San Diego, California • Melbourne, Florida • Peoria, Illinois",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Melbourne",
          "state": "Florida"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03014089"
    },
    {
      "nct_id": "NCT06733675",
      "title": "Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteer",
        "Pharmacokinetics",
        "Safety",
        "Drug-Drug Interaction (DDI)",
        "FDC"
      ],
      "interventions": [
        {
          "name": "Ledaborbactam etzadroxil",
          "type": "DRUG"
        },
        {
          "name": "Ceftibuten",
          "type": "DRUG"
        },
        {
          "name": "Ceftibuten-ledaborbactam etzadroxil",
          "type": "DRUG"
        },
        {
          "name": "Esomeprazole",
          "type": "DRUG"
        },
        {
          "name": "amoxicillin-clavulanate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Basilea Pharmaceutica",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 96,
      "start_date": "2025-01-07",
      "completion_date": "2026-12-30",
      "has_results": false,
      "last_update_posted_date": "2026-07-09",
      "last_synced_at": "2026-10-04T08:15:19.986Z",
      "location_count": 1,
      "location_summary": "Lenexa, Kansas",
      "locations": [
        {
          "city": "Lenexa",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06733675"
    },
    {
      "nct_id": "NCT05586152",
      "title": "Study of INV-102 Ophthalmic Solution in Adults With Moderate Symptomatic Dry Eye Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Dry Eye Disease"
      ],
      "interventions": [
        {
          "name": "INV-102",
          "type": "DRUG"
        },
        {
          "name": "Vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Invirsa, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 84,
      "start_date": "2022-08-30",
      "completion_date": "2023-05-02",
      "has_results": true,
      "last_update_posted_date": "2026-09-18",
      "last_synced_at": "2026-10-04T08:15:19.986Z",
      "location_count": 1,
      "location_summary": "Rush, New York",
      "locations": [
        {
          "city": "Rush",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05586152"
    },
    {
      "nct_id": "NCT06746259",
      "title": "FebriDx® Method Comparison Study Protocol",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Acute Respiratory Infections (ARIs)"
      ],
      "interventions": [
        {
          "name": "Rapid point of care test to detect host immune response in ARI",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Lumos Diagnostics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "12 Years to 64 Years"
      },
      "enrollment_count": 800,
      "start_date": "2024-12-20",
      "completion_date": "2025-08-31",
      "has_results": false,
      "last_update_posted_date": "2025-09-09",
      "last_synced_at": "2026-10-04T08:15:19.986Z",
      "location_count": 8,
      "location_summary": "Fullerton, California • Pasadena, California • Miami, Florida + 5 more",
      "locations": [
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miramar",
          "state": "Florida"
        },
        {
          "city": "Orange City",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06746259"
    },
    {
      "nct_id": "NCT04649541",
      "title": "Study of the Safety, Tolerability, and PK of MRX-8 Administered Intravenously to HVs in SAD and MAD Cohorts",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Safety"
      ],
      "interventions": [
        {
          "name": "MRX-8",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MicuRx",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 69,
      "start_date": "2020-11-29",
      "completion_date": "2021-12-01",
      "has_results": false,
      "last_update_posted_date": "2023-08-24",
      "last_synced_at": "2026-10-04T08:15:19.986Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04649541"
    },
    {
      "nct_id": "NCT05875961",
      "title": "Study to Evaluate Immunogenicity, Safety and Tolerability of Adjuvanted and Non-Adjuvanted H2N3 Influenza Vaccines in Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Influenza, Human",
        "Infections",
        "Respiratory Tract Infections",
        "Virus Diseases",
        "Infection Viral"
      ],
      "interventions": [
        {
          "name": "Low dose A/H2N3c + standard dose MF59",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Intermediate dose A/H2N3c + standard dose MF59",
          "type": "BIOLOGICAL"
        },
        {
          "name": "High dose A/H2N3c + standard dose MF59",
          "type": "BIOLOGICAL"
        },
        {
          "name": "High dose A/H2N3c non-adjuvanted",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Lowest dose A/H2N3c + high dose MF59",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Low dose A/H2N3c + high dose MF59",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Seqirus",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 600,
      "start_date": "2023-06-15",
      "completion_date": "2024-11-15",
      "has_results": false,
      "last_update_posted_date": "2026-09-21",
      "last_synced_at": "2026-10-04T08:15:19.986Z",
      "location_count": 3,
      "location_summary": "Rockville, Maryland • Lincoln, Nebraska • Omaha, Nebraska",
      "locations": [
        {
          "city": "Rockville",
          "state": "Maryland"
        },
        {
          "city": "Lincoln",
          "state": "Nebraska"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05875961"
    },
    {
      "nct_id": "NCT07104162",
      "title": "A Study to Investigate Safety and Pharmacokinetics of Intravenous Cefiderocol/Xeruborbactam in Participants With Renal Impairment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Bacterial Infections"
      ],
      "interventions": [
        {
          "name": "Cefiderocol/Xeruborbactam",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Qpex Biopharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 40,
      "start_date": "2025-09-16",
      "completion_date": "2026-09-04",
      "has_results": false,
      "last_update_posted_date": "2026-09-25",
      "last_synced_at": "2026-10-04T08:15:19.986Z",
      "location_count": 2,
      "location_summary": "Miami, Florida • Orlando, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07104162"
    },
    {
      "nct_id": "NCT03518125",
      "title": "BARDA Securing Anthrax Immunity For the Elderly",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anthrax"
      ],
      "interventions": [
        {
          "name": "BioThrax",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AV7909",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sodium chloride injection USP, 0.9% (placebo)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Biomedical Advanced Research and Development Authority",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 305,
      "start_date": "2018-05-09",
      "completion_date": "2019-12-09",
      "has_results": true,
      "last_update_posted_date": "2020-07-21",
      "last_synced_at": "2026-10-04T08:15:19.986Z",
      "location_count": 4,
      "location_summary": "Lenexa, Kansas • Mt. Pleasant, South Carolina • Nashville, Tennessee + 1 more",
      "locations": [
        {
          "city": "Lenexa",
          "state": "Kansas"
        },
        {
          "city": "Mt. Pleasant",
          "state": "South Carolina"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03518125"
    },
    {
      "nct_id": "NCT06803342",
      "title": "A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Sudan Ebolavirus Vaccine in Healthy Adults",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ebola Sudan Virus Disease"
      ],
      "interventions": [
        {
          "name": "cAd3-Sudan Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Albert B. Sabin Vaccine Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 200,
      "start_date": "2025-06-26",
      "completion_date": "2027-04",
      "has_results": false,
      "last_update_posted_date": "2026-02-10",
      "last_synced_at": "2026-10-04T08:15:19.986Z",
      "location_count": 4,
      "location_summary": "Phoenix, Arizona • Melbourne, Florida • Chicago, Illinois + 1 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Melbourne",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06803342"
    }
  ]
}